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Background: Low back pain (LBP) is one of the leading causes of disability and has a major socioeconomic impact.
Despite a large amount of research in the field, there remains uncertainty about the best treatment approach for
chronic LBP, and identification of relevant patient subgroups is an important goal. Exercise therapy is a commonly
used strategy to treat chronic low back pain and is one of several interventions that evidence suggests is
moderately effective.
In parallel with an update of the 2005 Cochrane review, we will undertake an individual participant data (IPD) meta-
analysis, which will allow us to standardize analyses across studies and directly derive results, and to examine
differential treatment effects across individuals to estimate how patients’ characteristics modify treatment benefit.
Methods/design: We will use standard systematic review methods advocated by the Cochrane Collaboration to
identify relevant trials. We will include trials evaluating exercise therapy compared to any or no other interventions
in adult non-specific chronic LBP. Our primary outcomes of interest include pain, functional status, and return-to-
work/absenteeism. We will assess potential risk of bias for each study meeting selection criteria, using criteria and
methods recommended by the Cochrane BRG.
The original individual participant data will be requested from the authors of selected trials having moderate to low
risk of bias. We will test original data and compile a master dataset with information about each trial mapped on a
pre-specified framework, including reported characteristics of the study sample, exercise therapy characteristics,
individual patient characteristics at baseline and all follow-up periods, subgroup and treatment effect modifiers
investigated. Our analyses will include descriptive, study-level meta-analysis and meta-regression analyses of the
overall treatment effect, and individual-level IPD meta-analyses of treatment effect modification. IPD meta-analyses
will be conducted using a one-step approach where the IPD from all studies are modeled simultaneously while
accounting for the clustering of participants with studies.
Discussion: We will analyze IPD across a large number of LBP trials. The resulting larger sample size and consistent
presentation of data will allow additional analyses to explore patient-level heterogeneity in treatment outcomes
and prognosis of chronic LBP.
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Low back pain (LBP) is one of the leading causes of dis-
ability and has a major socioeconomic impact [1-5]. The
majority of the cost associated with LBP is generated by
a small percentage of patients whose condition proceeds
to chronicity [6,7]. There is evidence that the prevalence
and costs of chronic LBP are rising [8]. Exercise therapy
is a commonly used strategy to treat chronic LBP in and
is one of several interventions which evidence suggests
is moderately effective [9].
In back pain research, identification of relevant patient
subgroups is an important goal [10]. Previous interac-
tions with clinical stakeholders identified the lumping
together of heterogeneous patients who have non-
specific LBP, as a source of frustration in LBP interven-
tion research [11]. There is a presumption that relevant
subgroups of individuals with chronic LBP exist, and
that our lack of understanding hampers clinical deci-
sion-making.
Treatment effect modification occurs when the treat-
ment effect is consistently better for a subgroup of indi-
viduals than for the group as a whole. One or more
characteristics (treatment effect modifiers) can define
treatment-based subgroups (see Kamper et al., 2010, for
a discussion of treatment-based subgroups) [12]. Promis-
ing treatment effect modifiers can come from previous
research findings, and clinical or biological rationale.
Prognostic factors (characteristics associated with out-
come over time) are not necessarily treatment effect
modifiers. For LBP there is little conclusive evidence on
treatment effect modifiers, although identifying relevant
treatment subgroups has been a goal in recent years.
LBP has been classified in many ways: on the basis of
pathoanatomy, presence/absence of specific signs or
symptoms (for example, sciatica), the duration of symp-
toms (acute, subacute, chronic), work status, diagnostic
testing, patient history, or combinations of these. Sys-
tems and tools used to classify and subgroup patients
with LBP were reviewed by Binkley et al. (1993) [13],
Fritz et al. (2005) [14], and Karayannis (2012) [15]; Kam-
per et al. (2010) [12], discuss research on subgrouping in
LBP. These authors report difficulties with most existing
subgroup/classification systems, including unclear reli-
ability or validity in clinical practice, non-comprehensive
selection of predictor variables, and inclusion of
measures or information that are not useful, nor feasibly
collected in primary-care practice. Furthermore, most
LBP trials are underpowered to detect treatment effect
modifiers [16].
Systematic review is a study design that uses transpar-
ent and robust methods to search the literature, select
appropriate studies, extract relevant data, assess risk of
bias, and synthesize and interpret research evidence for
a specific question [17]. This is an extremely usefulapproach to summarize evidence about treatment effect-
iveness based on a complete body of literature. Meta-
analysis, which is the quantitative synthesis of data from
primary studies, is valuable to increase the number of
patients (statistical power/precision) available to esti-
mate a treatment effect, to better distinguish a clinically
important true treatment effect from chance effects, and
to identify and investigate sources of between-study het-
erogeneity in the magnitude of the treatment effect.
Traditional meta-analyses that collect published aggre-
gate study data and pool studies to estimate one overall
effect have limitations: in particular, they often bring to-
gether heterogeneous information which, some argue,
limits their relevance to managing individual patients in
clinical practice [18]. An alternative approach to
evidence synthesis is meta-analysis of individual partici-
pant data (IPD), where the raw individual-level data are
obtained for each study and used for synthesis. IPD
relates to the data recorded for each individual in a
study. This is in contrast to aggregate data that relates to
information averaged or estimated across all individuals
in a study (for example, information on mean treatment
effect, mean age, proportion of male participants). Such
aggregate data are derived from the IPD itself, so IPD
can be considered the original source material. IPD
meta-analyses are increasingly achievable [19].
The use of IPD has numerous potential advantages.
Aggregate data are often not available, are poorly
reported, or are derived and presented differently across
studies (for example, odds ratio versus relative risk).
They are more likely to be reported (and in greater de-
tail) when statistically significant, amplifying the threat
of publication bias. In contrast, IPD allows one to
standardize analyses across studies and directly derive
the information desired, independent of significance or
how it was reported. IPD may also allow a longer follow-
up time, more participants, and more outcomes than
were considered in the original study publication. This
means that IPD meta-analyses are potentially more reli-
able than aggregate data meta-analyses, and may lead to
different conclusions. Perhaps most importantly, an IPD
meta-analysis can produce more clinically relevant
results, going beyond the grand mean toward individua-
lized medicine and thereby reducing the heterogeneity
in study results [20]. For example, subgroups of patients
with a common characteristic (for example, female gen-
der) can be identified within IPD, and thus meta-analysis
results can be derived specifically for them, with
increased power compared to the individual studies
themselves. Similarly, IPD allows more powerful and re-
liable examination of differential treatment effects across
individuals [21,22], as one can directly utilize within-trial
information to estimate how patients’ characteristics
modify treatment benefit [23].
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framework of the Cochrane Collaboration to investigate
the effectiveness of exercise therapy for treating LBP; 61
trials were included [24-26]. We concluded that exercise
therapy appears to be effective in slightly decreasing pain
and improving function in adults with chronic LBP;
however, this earlier work was limited by the availability
of only published aggregate data. Since our 2005
Cochrane review, almost 150 new, potentially relevant,
randomized controlled trials (RCTs) have been pub-
lished, warranting an important update. The very large
number of recent trials available for this review provides
an opportunity for comprehensive and novel syntheses
beyond the Cochrane review and traditional meta-ana-
lyses. For exercise therapy, one small study is available
that attempted to identify individual characteristics for
patients likely to respond to stabilization exercises [27].
This highly cited study included 54 subjects and devel-
oped a clinical predictive rule. However, these results are
preliminary. Chou et al. (2010) note, More research on
methods for selecting optimal therapy that are practical
for use by primary care clinicians is urgently needed.
[28]. In this study we will investigate individual charac-
teristics that may modify treatment outcomes in exercise
therapy.
Study objectives
Our primary objective in this project is to assess treat-
ment effect and effect modification of exercise therapy
for reducing pain and disability in adults with chronic
LBP. We aim to identify subgroups of patients with LBP
who are more likely to benefit from specific approaches
of exercise therapy.
Methods/design
Identifying studies for systematic review
We will use standard systematic review methods advo-
cated by the Cochrane Back Review Group (BRG) to
identify relevant trials [29]. Complete descriptions of
systematic review methods for the related Cochrane re-
view are reported elsewhere [30]. The search strategy
will include a computerized search of electronic data-
bases since the last Cochrane update (2004 to current):
MEDLINE, EMBASE, PsychINFO, CINAHL, PEDro,
SportDiscus, and the Cochrane Central Register of Con-
trolled Trials. We will conduct citation searches of pre-
vious review publications [24-26] and screen cited
references of other exercise therapy systematic reviews.
We will contact content experts for additional trials.
Hand searches of key musculoskeletal journals are cap-
tured in the Cochrane Central Register searches.
We will not restrict the searches or inclusion criteria
to any specific languages. A standard protocol will be
followed for study selection and data abstraction [29].This includes two reviewers’ independent assessments of
study eligibility, data extraction, trial quality and clinical
relevance. Consensus and, if needed, a third reviewer
will be used to resolve disagreements.
We will identify and include RCTs evaluating exercise
therapy compared to any or no other interventions in
adult (> 18 years of age) non-specific (alone or with leg
pain) chronic (> 12 weeks duration) LBP. Trials with
mixed subacute (> 6 weeks duration) and chronic LBP
populations will also be eligible for the IPD meta-
analysis as it will be possible to extract information on
chronic participants. We will exclude studies that in-
volve individuals with LBP caused by specific pathologies
(for example, fracture, rheumatoid arthritis, infection,
neoplasm, or metastasis) or conditions (for example,
pregnancy). Exercise therapy is defined as a supervised
exercise program or formal home exercise regimen, ran-
ging from programs aimed at general physical fitness or
aerobic exercise, to those aimed at muscle strengthening
or stretching, and graded activity programs.
Our primary outcomes of interest include pain, func-
tional status, and return-to-work/absenteeism. Second-
ary outcomes of interest include global improvement/
perceived recovery, health-related quality of life, satisfac-
tion with treatment, reduction in frequency of analgesic
use, psychological measures (for example, self-efficacy,
fear, catastrophizing, mood) and adverse events. We will
extract outcome assessment data for all time periods
and group them for the purposes of disseminating the
analyses: short-term (post-treatment assessment; 6 to
12 weeks after randomization), medium-term (closest to
six months), and long-term follow-up (12 months or
more) measured from randomization. Pain and physical
function outcomes will be measured as continuous vari-
ables and each study’s results will be placed on a com-
mon 0 to 100 scale to facilitate comparison and
interpretability of the syntheses; return to work/absen-
teeism outcomes will be measured as time-to-event, if
possible, or as dichotomous data.
Data collection and management
Collection of aggregate data
We will extract relevant study data, including popula-
tion, intervention(s), comparison(s) and outcome infor-
mation (measure and timing) for each study, and deposit
these onto pre-tested standardized electronic (Microsoft
Access) forms. One author will extract data and a sec-
ond author will check data for accuracy. In prior work
we identified important intervention characteristics with
the assistance of clinical experts. Interventions will be
characterized by the exercise program design (individu-
ally designed, partially individually designed, or stand-
ard), delivery type (home exercises, supervised home,
group supervision, or individual supervision), dose/
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the type(s) of exercises (for example, muscle strengthen-
ing, stretching, coordination, mobilizing, flexibility)
(described in detail in Hayden et al., 2005) [26]. We will
contact primary study authors for additional information
when necessary.
We will assess potential risk of bias for each study
meeting selection criteria. Risk of bias will be assessed
by two independent reviewers, with consensus, using cri-
teria recommended by the Cochrane BRG [29]. We will
assess potential bias related to random sequence gener-
ation, allocation of treatment concealment, blinding of
participants and personnel, blinding of outcome assess-
ment, incomplete outcome data, selective outcome
reporting, and other sources of potential bias (similar
groups and co-interventions, compliance, timing). For
the IPD meta-analysis we will identify the subgroup of
selected trials that are rated as moderate to low risk of
bias defined as at least six of eleven items rated as
low risk of bias with no fatal flaws. We will judge
the likelihood of fatal flaws following Cochrane Hand-
book recommendations, including: 1) a drop-out rate
greater than 50% at the follow-up measurement period
of interest; 2) clinically relevant baseline differences for
one or more primary outcomes indicating unsuccessful
randomization; or 3) unacceptable adherence to the ex-
ercise program (defined as less than 50% adherence in
supervised programs).Collection of individual patient data
Identifying IPD studies
The original IPD will be requested from the authors of
selected studies with moderate to low risk of bias. We
will identify contact information for study authors from
PubMed or from the Internet and will email authors
listed as contact authors to tell them about our IPD
meta-analysis, and to ask if they are willing to share their
trial data. If there is no response from the contact au-
thor, another investigator from the study will be
contacted.
We have previously been in contact with authors of
included trials in this Cochrane review (for the purpose
of obtaining further information and clarification,
as well as to explore request of IPD from a small subset
of studies). In most cases we have received prompt as-
sistance from the authors, particularly from recently
published trials. We requested IPD from 12 high quality
trials included in the 2005 Cochrane Review update. We
received immediate responses from eleven of the twelve
authors and received datasets from four of these.
Authors who did not provide data reported no longer
having access to the data (many trials were > 5 years
since publication). Based on our prior experience, weexpect to identify approximately 30 to 40 higher quality
trials and anticipate having access to 20 to 30 datasets.
We will make four successful delivery attempts to con-
tact study authors (that is, two attempts each to the
listed contact author, and if needed, another study au-
thor). Study authors not responding or unwilling to con-
tribute their study data will be sent a final note inquiring
why they are unable to participate.
Collecting data
We will extract information about each eligible and
included IPD study, including the following additional
study-level information: reported characteristics of the
study sample, variables collected at baseline and follow-
up periods, and subgroup and treatment effect modifiers
investigated and presented in the report.
We will contact participating study authors to provide
additional information about the study and how to send
us their IPD. Methods for receiving raw data from inves-
tigators may vary depending on the security concerns of
their individual institutions; however, data may be
obtained by mail (via password-protected memory key
and couriered to Dalhousie University, Halifax, Canada),
by e-mail, or by a secure transfer system similar to the
Dalhousie File Exchange. After data have been received,
they will be stored on a secure institutional server.
We will accept databases in all formats in order to
minimize the amount of work for primary study authors;
however, ideally the format will be a two dimensional
spreadsheet format with one subject per row, and vari-
ables listed in columns.
Each raw dataset will be saved in its original format
and then converted to a common format. We will use
these common datasets to rename and label the vari-
ables for each included study in a consistent manner.
We will use a pre-specified preliminary framework for
mapping and classifying sufficiently similar variables
(Table 1). If in doubt, we will contact primary study
authors for clarification and/or discuss within the collab-
orative group.
Checking data
We will evaluate data from each study and compare
these to available publication(s). We will check each
dataset for the range of included variables to make sure
all values are reasonable. We will assess missing obser-
vations for each variable and check against the original
publication. We will attempt to replicate results reported
in the original publication, including baseline character-
istics and outcome data at each available follow-up
period, by reproducing the statistical methods as
reported by the study authors. We will discuss and clar-
ify any discrepancies or missing information between
our results and those presented in each original
Table 1 Preliminary list of potential baseline variables and constructs (based on Hayden, 2007 Appendix) [31]




Body mass index (BMI) or height and weight BMI or measured height and individual weight
Lifestyle factors
Recreational participation Participation in sports activities or hobbies
Physical fitness Physical fitness level
Smoking Smoking habits
Alcohol consumption Amount/frequency of drinking, how often drunk
Coffee consumption Coffee consumed per day
Sociodemographic characteristics
Socio-economic status Education status, income
Work characteristics Employed, occupation
Social support Marital status
Overall health
General health status Perceived or self-rated health, general health question or Short Form-12, perceived energy level
Comorbidities Presence and type of co-morbidities (for example, musculoskeletal pain other than LBP, respiratory or
stomach problems, migraines, multiple pain sites)
Previous injuries Previous sick leave (any cause or other than LBP), or accident
Receipt of compensation or litigation
Worker’s compensation; time off work; sick
leave; benefits; pension
Receipt of worker’s compensation, duration of time off work, sick leave due to LBP, benefits paid,
pension application applied for or intending to apply for
Attribution for LBP Litigation, culpability for injury, job that caused pain, description of injury event
Previous low back pain (before the current episode)
Previous history of LBP Report of prior LBP
Previous LBP treatment received (for example, injections, inpatient treatment, surgery)
Prior claim for LBP, LBP sick leave, worker’s compensation injury
Hospitalization due to LBP, previous lumbar spine radiography
Characteristics of the current LBP episode
Pain onset Onset of injury (for example, sudden or gradual), injury event or none
Duration of complaint LBP duration, time between injury and filing claim
Baseline LBP symptoms
Pain severity Injury severity rating, presence of disabling pain, visual analogue scale, presence of pain at night, NRS;
McGill scale
Functional limitations Disability score (for example, RMDQ, Oswestry), assessment of functioning in leisure time
Change in symptoms Symptoms getting worse or better
Baseline physical examination findings
Range of motion (ROM) Change in ROM
Pain pattern (centralization) Pain pattern/directional preference according to McKenzie method
Other examination findings Summed physical exam, SLR, muscle palpation, gait, posture, walk test, ‘catch’, Waddell symptoms
Baseline neurological findings
Localization; nerve root; radiculopathy; pain
on coughing
Localization of pain to low back only, presence of nerve root signs/symptoms, clinical impression of
radiculopathy with SLR, pain on coughing
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Table 1 Preliminary list of potential baseline variables and constructs (based on Hayden, 2007 Appendix) [31]
(Continued)
Subject psychological status
Depression Rating scale of ‘feeling blue’, Beck Depression Inventory, GHQ depression scale, Zung Self-Rating
Depression Scale
Other psychological diagnoses For example, hysteria, somatic symptoms, hypochondriasis
Other psychological characteristics and
behaviors
For example, self-esteem, pain behaviors, denial, state of anxiety, sleep problems, locus of control, fear
avoidance beliefs, personality measures, active/passive coping mechanisms
LBP diagnosis received
Diagnostic categories Specific diagnostic categories (for example, sprain/strain, disc herniation)
Understanding of symptoms Patient’s understanding and accuracy of their symptoms
Subject expectations of recovery
Subjective work ability Subjective work capacity in relation to complaint
Perceived ability to do job Perceptions regarding ability to do job, expectations with injury
Psychosocial capacity to RTW Psychosocial capacity to RTW, Worker Role Interview
Intent/expectations to RTW Intent/expectations to return to job
Other baseline/LBP episode characteristics
NRS: numeric rating scale.
RMDQ: Roland Morris Disability Questionnaire.
SLR: straight leg raise.
GHQ: general health questionnaire.
RTW: return to work.
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able to reproduce published trial findings or explain dis-
crepancies, these trials will not be included in our IPD
synthesis.
Once data checks are complete and satisfactory, indi-
vidual study datasets will be combined to form a new
master dataset with a variable added to indicate the ori-
ginal study.
Preparing data for analyses
The complete master database will be maintained for fu-
ture collaborative initiatives as long as study authors are
in agreement. As described below, we intend that the
collaborative group will grow and continue to collabor-
ate with future pre-specified analyses. For the current
analysis a subset of the master database will be identi-
fied, including studies that collected data on pre-
specified baseline factors. This will allow multivariable
regression analyses that are theory-driven and evidence-
informed with an aim to replicate and extend knowledge
about treatment effect modifiers for chronic LBP. We
will collect data from variables in the following domains:
subject characteristics, lifestyle factors, sociodemo-
graphic characteristics, overall health, receipt of com-
pensation/litigation, previous LBP, characteristics of the
current episode, physical examination findings, psycho-
logical status, expectations (see Table 1). Whenever pos-
sible, we will maintain data for continuous measurement
of variables. For all variables, we will preferentially select
measures that are most reliable and have minimalmeasurement error. If data on a variable of interest are
not available in the dataset, we will attempt to extract
this information based on other data in the set.
We will assess subject-level missing data on variables
and outcomes. Individual subjects with missing outcome
data within each trial will generally be excluded from
that specific analysis, though we will check that such ex-
clusion does not impact upon baseline balance. Missing
baseline variable data will be handled using multiple im-
putation techniques, under a missing-at-random as-
sumption, so as to avoid excluding patients from the
analysis and to ensure baseline balance between treat-
ment groups is maintained [32,33].
Synthesis strategy
Descriptive analyses
We will describe study-level and patient-level character-
istics of included studies. We will compare study-level
characteristics and aggregate data from studies partici-
pating in the IPD analysis with those from studies that
are eligible but do not supply data to the collaborative;
we will examine if the IPD studies available are a repre-
sentative (unbiased) sample of the full set of existing
studies, as recommended by Ahmed et al. (2012) [34].
Study-level meta-analysis and meta-regression analyses of
the overall treatment effect
Meta-analysis and meta-regression analyses based on ag-
gregate data presented in the publications of primary
studies will be conducted as part of the associated
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data on the effect of exercise treatment, and assess the
impact of study-level variables including exercise inter-
vention characteristics. These methods are described
elsewhere [30], and include (separately for each outcome
and each intervention) a random-effects meta-analysis to
estimate the pooled (average) treatment effect and its
95% CI [35]; the amount of between-study heterogeneity
(quantified by I2 and tau-squared) [36]; and a 95% pre-
diction interval for the potential treatment effect in a
single clinical setting [37].
Additional analyses (again, separately for each out-
come and each intervention) will repeat the meta-
analyses using the primary trial IPD available. These IPD
meta-analyses will be conducted using a one-step ap-
proach, where the IPD from all studies are modeled sim-
ultaneously while accounting for the clustering of
participants within studies. The model used will relate to
the type of outcome being synthesized, but will include a
linear analysis of covariance model (for continuous out-
comes adjusting for baseline value), a logistic regression
model (for binary outcomes), and a Cox regression or
related survival model (for time-to-event outcomes).
The pooled treatment effect of exercise therapy will be
estimated according to a mean difference (for continu-
ous outcomes), an odds ratio (for binary outcomes) and
a hazard ratio (for time-to-event outcomes) and their
95% CIs, based on the intention-to-treat (ITT) principle
in the database that includes IPD from all trials, clus-
tered by trial. These analyses will allow us to compare
results using the IPD studies with results using aggregate
data from the full set of studies, to ascertain if and
how the IPD analysis alone differs to an aggregate data
meta-analysis of all studies in terms of the treatment ef-
fect obtained.
Where possible, for each analysis we will compare the
effect of each exercise therapy considering the duration
of the exercise program and any outcome follow-up
(time course). We will recognize that this is a study-level
comparison, and thus subject to potential study-level
confounding.
Individual-level IPD meta-analyses of treatment
effect modification
In addition to the analyses above, the IPD studies will
be used to examine treatment effect modification at
patient level, where individual patient characteristics
are associated with changes in the treatment response.
Candidate predictors of treatment response may be
identified by considering biological (including behavioral
and sociocultural) or other mechanisms for modification
of treatment response (biological reasoning and by
understanding the mechanism by which response is
modified), and from existing prognostic research(treatment effect modification studies [38] and prognos-
tic factor research [39]).
We will consider the (limited) LBP research evidence
on treatment effect modifiers, and prognostic factors
with causal or mechanistically relevant effects. Candidate
predictors of treatment response that we will consider in
our primary analyses include age, duration of symptoms,
severity of symptoms/bothersomeness, radicular signs/
symptoms, leg symptoms, directional preference, fear
avoidance beliefs, depression, social support, general
health, acceptance of treatment, and popular clinical
prediction models, for example, STarT Back (Hill, 2010)
[40], or Delitto’s treatment-based classification (Brennan,
2006) [41].
For each analysis of the overall treatment effect
described above, we will identify studies that have add-
itional data for baseline variables that are potential (can-
didate) predictors of treatment response for one or more
of the outcomes of interest. For each of these candidate
predictors of treatment response we will present treat-
ment effects for subgroups defined by the predictor, and
test for an interaction between each predictor and the
effect of treatment on pain and disability outcomes. We
will extend the one-step IPD meta-analysis framework
described above to include multiple variables and inter-
action terms between treatment and each variable; the
analysis will again account for the clustering of patients
within studies, and carefully separate out within-study
interaction terms (patient-level) and between-study
interaction terms (study-level) to avoid ecological bias
[42,43]. We will consider a variable as a clinically im-
portant effect modifier if the within-study interaction co-
efficient is statistically significant at P < 0.05 and if the
subgroup treatment effects differ by either 10% or more,
or another magnitude deemed clinically important by
experts. On the basis of current literature on minimal
clinically important differences, we will consider an
average 20-point (/100) improvement in pain [44]
and 10-point (/100) improvement in functioning out-
comes [45] to be clinically important. We will consider
clinically important individual patient response as
any improvement in score ≥ 30% of its baseline value,
with a minimum value of 20-point (/100) improve-
ment in pain and 10-point (/100) improvement in
functioning [46,47].
Sensitivity analysis
The robustness of conclusions to the exclusion of stud-
ies without a low risk of bias will also be examined in a
sensitivity analysis.
Investigation of small study effects
For the overall treatment effect investigations, any meta-
analysis containing 10 or more studies will be examined
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studies to provide more significant and positive find-
ings than larger studies. For this purpose contour
enhanced funnel plots [48] and tests for funnel
plot asymmetry will be utilized, according to recent
recommendations [49].Statistical software
Descriptive and aggregate level data analyses will be con-
ducted using Stata (StataCorp LP, Texas, USA), and Rev-
Man 5 (The Nordic Cochrane Centre, Copenhagen,
Denmark) software. The one-stage IPD meta-analysis
models will primarily be conducted using Stata or SAS.
However, if model complexity warrants, a Bayesian Mar-
kov Chain Monte Carlo method will also be considered
and fitted using the Bayesian software, WinBUGS
[50,51]. All IPD analyses conducted will be based on the
checked and updated IPD from all eligible available
trials. Study data will not be used for any other purpose
without the permission of collaborators.IPD MA group collaboration
The local project team is responsible for the project’s
management decisions and daily management of the col-
laboration. The project team developed the initial proto-
col and will organize interactions with the collaborative
group. The project team will act as a liaison between
members of the collaborative group.
The collaborative group, the Chronic Low Back Pain
IPD Meta-Analysis Group (LBP-IPD Group), will be
composed of a representative from each of the included
trials. We will invite new collaborators as new eligible
studies are completed.
Members of the LBP-IPD Group will be given oppor-
tunities to participate in decision-making regarding the
study design and analyses. A primary publication of the
results of this review will be prepared by the project
team, and circulated to the collaborative group for crit-
ical comment. We will follow recommendations for
authorship in IPD analyses of Stewart & Tierney (2002)
[52], where core project team members and the collab-
orative group (the LBP-IPD Group) are listed as authors.
Participating members of the collaborative group will be
named in acknowledgement.
Members of the LBP-IPD Group will have opportun-
ities to network and participate in future collaborative
projects. We intend to pursue other important questions
suitable for analysis with the IPD dataset, some led by
other members of the collaborative. Once the collabora-
tive group and initial dataset are established we will de-
velop mechanisms for communication and input on
methodological issues.Ethics
The protocol for this IPD meta-analysis study has been
approved by the Dalhousie University Research Ethics
Board (REB). We will be synthesizing anonymous data
from previous clinical trials where consent will already
have been obtained by the original investigators. The
REB waived the requirement for obtaining additional
informed consent from participants, as the risks to parti-
cipants are minimal (data have already been collected
and published), obtaining consent is practicably impos-
sible (our review will draw from studies that have been
conducted in different countries, with different popula-
tions, some years past), no therapeutic intervention is
involved in the research (the original clinical studies will
have administered various treatments or interventions to
their participants, but we are not doing so), and the wai-
ver does not violate the rights or well-being of the parti-
cipants (all participants have already completed their
treatment and will have signed consent forms at the time
of the original studies). The principal author on each
study contributing data will be asked to sign a consent
form giving the project team permission to use their
data and specifying any restrictions on data usage/stor-
age they may wish to impose.
Discussion
In this project we will establish a collaborative group
and explore and analyze methods and results across a
large number of RCTs in the field of LBP. This and
related projects [30] will provide a unique opportunity
to investigate research methods and gaps in the litera-
ture, including comparing results of meta-analysis using
standard aggregate-level approaches, multi-treatment
meta-regression, and IPD. This project, as well as future
collaborative projects, will also help improve quality, de-
sign and reporting of LBP trials with respect to collec-
tion of information on prognostic factors relevant to the
identification of treatment subgroups (similar to the very
successful IMPACT project) [53].
The advanced methods that we propose in this project
use raw data from RCTs of exercise therapy to explore
patient characteristics and identify subgroups based on
their likely response to treatments. This approach is not
possible using meta-analysis of published aggregate data,
as subgroup effects are prone to bias and selective
reporting (they are not usually the primary objective of
the original trial). Furthermore, a meta-analysis of aggre-
gate data has low power to detect true effect modifiers
and is subject to study-level confounding and ecological
bias [19,54]. These problems are avoided by using
individual-level data.
There are several advantages of IPD meta-analysis that
we will exploit in this study: first, the availability of data
(increased sample size, more follow-up data); second,
Hayden et al. Systematic Reviews 2012, 1:64 Page 9 of 10
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formation independent of reporting, and standardization
of analyses across studies will mean more usable data for
meta-analyses), and third, additional analyses to explore
heterogeneity (more extensive use of available data to
explore study-level and patient-level factors in meta-ana-
lyses, and assessment of the variation in summary effect
within patient subgroups to allow better understanding
of the effects of treatments). This should lead to more
reliable and clinically informative meta-analysis results.
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